CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(01): 59-65
DOI: 10.4103/0971-5851.177038

Hodgkin lymphoma: A clinicopathological and immunophenotypic study

Kaumudi Konkay
Department of Pathology, Nizam′s Institute of Medical Sciences, Hyderabad, Telangana, India
Tara Roshni Paul
Department of Pathology, Nizam′s Institute of Medical Sciences, Hyderabad, Telangana, India
Shantveer G Uppin
Department of Pathology, Nizam′s Institute of Medical Sciences, Hyderabad, Telangana, India
Digumarti Raghunadha Rao
Department of Medical Oncology, Nizam′s Institute of Medical Sciences, Hyderabad, Telangana, India
› Author Affiliations
Financial support and sponsorship Nil.


Introduction: The diagnosis of Hodgkin lymphoma (HL) is defined in terms of its microscopic appearance (histology) and the expression of cell surface markers (immunophenotype). Aims and objectives: This study aims to analyze the clinical features, histomorphology, and immunoprofile of over 200 patients of HL diagnosed over a period of 4 years at our institute and to determine relative frequency of various histological subtypes (based on WHO classification) in relation to age and sex distribution in this part of the country. Materials and Methods: All HL cases diagnosed between January 2006 and December 2009 were retrieved from hospital records. The histopathology of both lymph node and bone marrow biopsy (where ever available) along with immunohistochemistry (CD15, CD30, CD20, and ALK) were reviewed. Results: There was a bimodal age distribution. HL affected people a decade earlier than in the western population. The most common presenting complaint was cervical lymphadenopathy. Mixed cellularity was the most frequent subtype (67%), followed by nodular sclerosing subtype (23.5%). Group A (CD15+, CD30+, CD20−), which represents the archetypical immunophenotype of classical HL (CHL) was the most common type (60.6%). The number of CD15 negative CHL was 35.8% and CD20 positive CHL was 17.5%. CD15 negativity with CD20 positivity was seen in 5% CHL. One out of seven CD20 positive CHL patients showed relapse. Conclusion: In this paper, we have discussed in detail about various clinical and histopathological parameters of HL and their relative frequency in various histological subtypes. This paper is being presented as it is a rather large study from India taking into consideration the clinical, pathologic, and immunophenotypic profile of the patients.

Publication History

Article published online:
12 July 2021

© 2016. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 von Wasielewski S, Franklin J, Fischer R, Hübner K, Hansmann ML, Diehl V, et al. Nodular sclerosing Hodgkin disease: New grading predicts prognosis in intermediate and advanced stages. Blood 2003;101:4063-9.
  • 2 von Wasielewski R, Mengel M, Fischer R, Hansmann ML, Hübner K, Franklin J, et al. Classical Hodgkin′s disease. Clinical impact of the immunophenotype. Am J Pathol 1997;151:1123-30.
  • 3 Stein H,Delsol G, Pileri SA, Weiss LM, Poppema S, Jaffe ES. Hodgkin lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoetic and Lymphoid Tissues. 4 th ed. Lyon, France: IARC Press; 2008. p. 321-34.
  • 4 Patkar N, Mehta J, Kulkarni B, Pande R, Advani S, Borges A. Immunoprofile of Hodgkin′s lymphoma in India. Indian J Cancer 2008;45:59-63.
  • 5 Barakzai MA, Pervez S. CD20 positivity in classical Hodgkin′s lymphoma: Diagnostic challenge or targeting opportunity. Indian J Pathol Microbiol 2009;52:6-9.
  • 6 Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK, et al. Consolidation radiation after complete remission in Hodgkin′s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need? J Clin Oncol 2004;22:62-8.
  • 7 Arya LS, Dinand V, Thavaraj V, Bakhshi S, Dawar R, Rath GK, et al. Hodgkin′s disease in Indian children: Outcome with chemotherapy alone. Pediatr Blood Cancer 2006;46:26-34.